Source: International Congress 2014 – ILDs 4
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Ichimura, K. Tsushima, T. Matsumura, A. Yokota, J. Terada, K. Iesato, S. Sakao, Y. Tada, N. Tanabe, K. Tatsumi (Chiba, Japan). The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital. Eur Respir J 2014; 44: Suppl. 58, 3755

Member's Comments

No comment yet.

Related content which might interest you: Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical findings at initial presentation of IPF patients at a university hospital referral center Source: International Congress 2014 – ILDs 5 Year: 2014 Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience Source: International Congress 2014 – ILDs 2 Year: 2014 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014